Trametinib
Anaplastic Pleomorphic Xanthoastrocytoma
National Cancer Institute (NCI)Small moleculePhase 4 / ApprovedActive
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 54/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Anaplastic Pleomorphic Xanthoastrocytoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Dabrafenib National Cancer Institute (NCI) | Phase 4 | BB |
Carboplatin Novartis Pharmaceuticals | Phase 2 | B |
(+)-VINCRISTINE Novartis Pharmaceuticals | Phase 2 | B |
Binimetinib Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | CCC |
Encorafenib Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 | CCC |
View all 9 →
Same molecule, other indications
Trametinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →